Chemical Constituents of Prangos tschimganica; Structure Elucidation and Absolute Configuration of Coumarin and Furanocoumarin Derivatives with Anti-HIV Activity. by Shikishima, Y. et al.
Prangos tschimganica belongs to the Umbelliferae and is
distributed throughout Central Asia. This family is well
known for producing a large number of coumarins with iso-
prenoid units disposed in multifarious ways.1—3) This family
also has been found to be relatively rich in secondary meta-
bolic products, such as furocoumarin,4,5) which have attracted
considerable interest due to their biological activity, and their
chemical and physical properties have been investigated ex-
tensively.6) The aerial parts of P. tschimganica are used in
Uzbekistan as a folk medicine for skin conditions such as
leukoplakic disease. In the course of our search for bioactive
metabolites from herbal plants in Uzbekistan, we have been
studying the chemical components of this plant. We de-
scribed here in the structural determination of three new
coumarin derivatives (1—3) and 30 known compounds (4—
33) isolated from P. tschimganica.
Repeated column chromatography of the n-BuOH and
EtOAc soluble fractions from the methanol extracts of the
dried aerial parts of P. tschimganica yielded compounds 1—
33.
Compound 1 was obtained as a colorless oil, and its mole-
cular formula was determined to be C22H28O10 on the basis of
high resolution (HR)-FAB-MS. Its IR spectrum showed the
presence of an a ,b-unsaturated lactone (1730 cm21), ester
(1700 cm21), a hydroxy group (3422 cm21) and an aromatic
ring (1625 cm21). The UV spectrum exhibited absorption
bands characteristic of coumarin at 321, 264 and 250 nm.
The 1H-NMR spectrum of 1 showed the presence of two a-
pyron protons [dH 7.78, 6.23 (each 1H, d, J59.5 Hz)], one
AB-type aromatic proton [dH 7.47, 7.01 (each 1H, d,
J58.7 Hz)], two methyl groups [dH 1.31, 1.29 (each 3H, s)]
and one methoxyl group [dH 3.99 (3H, s)]. The 13C-NMR
spectrum exhibited 22 carbon resonances including two
methyls, one methoxy, three methylenes, eight methines, two
carbonyl carbons and six quaternary carbons (Table 1). The
13C-NMR spectral data of 1 were very similar to those of
meranzin hydrate (see Experimental),7) except for the pres-
ence of seven carbon signals in compound 1. In the 1H–1H
correlation spectroscopy (COSY) spectrum of 1, the proton
signal at dH 1.63 (H2-60) was correlated with dH 3.86 (H-50);
dH 3.26 (H-40) with dH 3.86 and 3.90 (H-30); dH 1.41 (H2-20)
with dH 1.89 (H2-60) and 3.90, suggesting that the remaining
signals reflected a quinic acid moiety. In the heteronuclear
multiple bond correlation (HMBC) spectrum of 1, the proton
signals at dH 3.45 (H2-19) and 3.08 (H2-19) were correlated
with the carbon signals at dC 162.5 (C-7), 154.6 (C-8a) and
114.6 (C-8); dH 7.78 (H-4) with dC 154.6; dH 5.23 (H-29)
with dC 175.6 (C-70); and dH 3.99 (OCH3) with dC 162.5.
These findings clearly indicated that the isoprene unit was
connected to C-8 of the coumarin ring (Fig. 1), and car-
boxylic acid (C-70) was connected to C-29 of the isoprene
unit, while a methoxy function was connected to C-7. The
depicted relative stereochemistry of the quinic ester moiety
was established on the basis of multiplicities and the nu-
clear Overhauser enhancement and exchange spectroscopy
(NOESY) spectrum. Significant correlations were observed
between the proton signal at dH 3.26 (Hax-40, dd, J52.9,
9.3 Hz) and the proton signals at dH 1.71 and 1.63 (Hax-20,
dd, J52.6, 14.5 Hz, Hax-60, t, J512.9 Hz); between dH 3.86
(Hax-50, ddd, J53.4, 9.3, 12.9 Hz) and dH 1.89 (Heq-60, dd,
J53.4, 12.9 Hz); between dH 3.90 (Heq-30, br s) and dH 1.71
(Hax-20) and 1.41 (Heq-20, dd, J52.9, 14.5 Hz). These spectral
results led us to propose the structure for tschimganic ester A
(1) except absolute configurations (Fig. 1).
Compound 2, obtained as a colorless oil, showed an
[M2H]2 peak at m/z 477 in its negative FAB-MS. Its UV ab-
sorption spectrum indicated the presence of a linear-type fu-
ranocoumarin (309, 267, 249, 221 nm), and its IR spectrum
showed absorption bands due to an a ,b-unsaturated lactone
(1727 cm21), a hydroxy group (3400 cm21), an aromatic ring
(1630 cm21) and a furan ring (883 cm21). The 1H-NMR spec-
trum showed two pairs of doublets in the downfield region,
one at dH 8.12 and 6.23 (J59.8 Hz) was attributed to the C-3
and C-4 protons of the coumarin nucleus while a second pair
of signals at dH 7.78 and 7.19 (J52.0 Hz) confirmed the
presence of the benzofuran moiety. The single aromatic pro-
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ton signal at dH 7.12 was assigned to the C-8 proton. The
13C-NMR spectrum showed 23 atoms, among which were 11
carbon atoms of the furanocoumarin nucleus, 5 carbons (dC
80.4, 73.2, 72.1, 27.5, 26.0) of the isoprene unit and 7 car-
bons consisting of two methylenes (dC 42.9, 38.7), three me-
thines (dC 77.0, 71.8, 68.4) and two quaternary carbons (dC
77.5, 175.4) (Table 1). These results were consistent with
C23H26O11 as molecular formula of 2, which was supported
by HR mass spectral data. The 1H- and 13C-NMR data of fu-
ranocoumarin and isoprene units in 2 were very similar to
those of oxypeucedanin hydrate (12),8) except for the pres-
ence of a signal assignable to the quinic acid moiety and the
chemical shifts at C-29 (2: d 80.4, 12: dC 76.5). In the
HMBC spectrum, the proton signals at dH 8.12 (H-4) and
4.89 (H2-19) were correlated with the carbon signal at dC
150.4 (C-5), suggesting that the isoprene unit was connected
to C-5. The proton signals at dH 5.34 (H-29) and 1.89 (H-20)
were correlated with the carbon signal at dC 175.4 (C-70), in-
dicating that the quinic acid group was located at C-29. The
relative stereochemistry was identified in the same manner as
described for 1. To determine the absolute stereochemistry of
positions 10, 30, 40 and 50 of the quinic acid moiety, com-
pound 2c and 2c9 were prepared by the reactions shown in
Chart 1. As shown, commercially available (2)-quinic acid
was treated with acetic anhydride in pyridine, to give
tetraacetylquinic acid (2a), which was treated with dicyclo-
hexylcarbodiimide (DCC), 4-pyrrolidinopyridine and 12 in
dichloromethane led to the compound 2b.9) The compound
2b (40 mg) was acetylated by using the same method with
acetic anhydride as that of esterification of oxypeucedanin
hydrate, to give the compound 2c (2 mg). Tetraacetylation of
2 with DCC and acetic anhydride gave 2c9 which was identi-
cal to compound 2c by comparison of TLC, 1H-NMR and
FAB-MS findings. In this synthesis, we used racemic com-
pound 12 (see later) so, compound 2 was concluded to be di-
astereomer on C-29. Based of these results, tschimganic ester
878 Vol. 49, No. 7
Chart 1
Fig. 1
Table 1. 13C-NMR Data for 1, 2 and 3
1 2 3
C-2 163.0 163.5 162.8
C-3 113.5 113.6 115.3
C-4 146.8 141.7 147.0
C-4a) 115.1 108.1 118.2
C-5 129.4 150.4 115.5
C-6 109.4 114.8 128.1
C-7 162.5 160.2 149.2
C-8 114.6 94.8 133.4
C-8a) 154.6 154.3 144.5
C-9 147.3 147.0
C-10 106.1 108.2
C-19 24.0 73.2 73.4
C-29 80.5 80.4 80.3
C-39 73.4 72.1 72.2
C-49 28.9 27.5 27.1
C-59 28.6 26.0 26.2
C-10 77.4 77.5 77.6
C-20 38.5 38.7 38.6
C-30 72.6 71.8 72.2
C-40 77.6 77.0 77.6
C-50 68.0 68.4 68.2
C-60 42.9 42.9 42.6
C-70 175.6 175.4 175.1
OCH3 57.2
a) CD3OD.
Table 2. Anti-HIV Activity of Compounds 4, 5, 9, 11 and 13
Compound IC50 (mg/ml) EC50 (mg/ml) TI
4 19.1 0.1 191
5 19.8 7.29 2.71
9 16.7 6.38 2.61
11 26.3 2.25 11.7
13 24.8 0.354 69.9
AZT 500 ,0.001 .500.000
AZT: azidothymidine
B could be represented by the formula 2 (Fig. 1).
Compound 3 was obtained as a colorless oil, and exhibited
a quasi-molecular ion peak at 477 in negative FAB-MS to
give a molecular formula of C23H26O11 in combination with
1H- and 13C-NMR data. The 13C-NMR spectra were very
close to those of 2, except for the signals due to C-5 and C-8
[3: dC 115.5 (d), 133.4 (s), 2: dC 150.4 (s), 94.8 (d)] (Table
1). This suggested the difference between these compounds
should be the linkage position of the isoprene unit. In the
HMBC spectrum of 3, the correlation of dH 4.62 (H2-19) with
133.4 (C-8) indicated the isoprene group was connected to
C-8. Other 1H- and 13C-NMR signals were assigned in the
same manner as described above. The structure of tschim-
ganic ester C was confirmed to be formula 3 (Fig. 1). While
many coumarin compounds have been isolated from natural
sources, this is the first isolation of two quinic acid ester of
coumarins (2, 3).
Based on a detailed study of spectral data, the known com-
pounds were identified to be psoralen (4), heraclenin (5), im-
peratorin (6), xanthotoxin (7), (6)-heraclenol (8), (6)-pabu-
lenol (9), isoimperatorin (10), (6)-saxalin (11), (6)-
oxypeucedanin hydrate (12), bergapten (13), (6)-8-(3-
chloro-2-hydroxyl-3-methylbutoxy)-psoralen (14) and xan-
thotoxol (15),9) pabularinone (16), osthol (17),10)
columbianetin (18), columbianetin-O-b-D-glucopyranoside
(19), (6)-auraptenol (20), isomeranzin (21),11) osthenol (22),
scopoletin (23), umbelliferone (24),12) tert-O-methylhera-
clenol (25) marmesin (26), (1)-ulopterol (27),13) (6)-
oxypeucedanin methanolate (28),14) desmethyl-7 suberosine
(29),15) isogospherol (30),16) (1)-peucedanol (31),17) yueh-
gesin-B (32),18) and marmesinine (33).19) Thus, P. tschimgan-
ica is rich source of coumarin derivatives.
To determine the absolute configurations and optical pu-
rity of the isolated compounds, the (R) and (S ) methoxytri-
fluoromethyl phenylacetic acid (MTPA) esters of coumarin
derivatives (20, 27, 31) and furanocoumarin derivatives (8, 9,
11, 12, 14, 28) were prepared by using a modified Mosher’s
method.20) The 1H-NMR spectral of coumarin-MTPA esters
(27, 31) showed a optically pure, and these were determined
to be R by comparison of its optical rotation with that re-
ported in the literature. However, the 1H-NMR spectral of
coumarin-(R or S) MTPA esters (20) showed separated pairs
on signals. This finding suggested that compound 20 should
be an enantiomeric mixture, and the ratio of two enan-
tiomeric isomers is about 1 : 3 [R : S] according to the integral
value of the separated signals. On the other hand, the 1H-
NMR spectral of furanocoumarin-MTPA esters also showed
separated pairs of signals. These results indicated that these
compounds should be an enantiomeric mixture, and the ratio
of two isomers is about 1 : 1 (8, 11, 12, 28), 6 : 4 (9) and 2 : 1
(14) according to the integral value of the separated signals.
Furthermore, the optical rotation values of furanocoumarin
derivatives (8, 9, 11, 12, 28) are near zero.
In our previous paper,21) we reported the isolation of
coumarin derivatives with anti-HIV activity. In this paper, we
report the anti-HIV activity22,23) of the isolated compounds
(Table 2). Psoralen (4) inhibited HIV-1 (IIIB strain) replica-
tion in H9 lymphocytes with an EC50 value of 0.1 mg/ml, and
it inhibited uninfected H9 cell growth with an IC50 value of
19.1 mg/ml; the therapeutic index (TI) was calculated to be
191. In general, TI.5.0 is considered to denote significant
activity; compounds 11 and 13 also showed potent anti-HIV
activities with TI values greater than 5.0.
Experimental
General Experimental Procedures NMR (400 MHz for 1H-NMR,
100 MHz for 13C-NMR, both use tetramethylsilane (TMS) as int. stand.)
were measured on a Bruker AM 400 spectrometer and MS spectra on a
JEOL JMS D-300 instrument; CC: Silica gel 60 (Merck), Sephadex LH-20
(Pharmacia) and Toyo pearl HW-40 (TOSOH); HPLC: GPC (shodex H-
2001, 2002, CHCl3; shodex GS-310 2G, MeOH), silica gel (Si 60, Hibar RT
250-25) and ODS (YMC-R-ODS-5; yamamura). IR spectra on a JASCO FT-
IR spectrometer (FT/IR-420) and 1720 FT-IR spectrometer (Perkin-Elmer),
UV spectra on a UV2100 UV-Vis recording spectrometer (Shimadzu). Opti-
cal rotations were measured with a JASCO DIP-370 digital polarimeter.
Plant Material The dried aerial parts of Prangos tschimganica were
collected in June 1998 from Uzbekistan. Herbarium specimens were de-
posited in the herbarium of the Institute of Botany, Academy of Sciences,
Uzbekistan. This plant was identified by Dr.Olimjon K. Kodzhimatov.
Extraction and Fractionation The dried aerial parts of P. tschimganica
were extracted three times with MeOH (10 l and 8 h each time) at 60 °C. The
combined extracts were concentrated under reduced pressure, the residue
(357 g) was diluted with water, and then extracted with AcOEt and n-BuOH,
respectively. The n-BuOH layer (44 g) was chromatographed over a silica gel
column (113100 cm, Merck Silica gel 60, 1 kg) and eluted with CHCl3–
MeOH (8 : 2 to 1 : 1). Thirteen fractions were obtained. Fraction 3 (3.8 g)
was chromatographed on Toyo pearl (5370 cm) with CHCl3–MeOH (2 : 1)
to give 4 fractions (3.1—3.4). Fraction 3.2 (2.7 g) was chromatographed
over silica gel (5380 cm, 300 g) and eluted with CHCl3–MeOH (8 : 2) to
give 3 fractions (3.2.1—3.2.3). Fraction 3.2.2 (852 mg) was separated by
general permeation chromatography (GPC) (MeOH), and gave further 8
fractions (3.2.2.1—3.2.2.8). Fraction 3.2.2.8 (48 mg) was isolated by HPLC
(ODS, MeOH–H2O, 3 : 1) to give compound 3 (4 mg). Fraction 3.2.3 (1 g)
was isolated by GPC (MeOH) to give 10 fractions (3.2.3.1—3.2.3.10). Com-
pound 1 (2 mg) was obtained after the purification of fraction 3.2.3.5
(26 mg) using HPLC (ODS, MeOH–H2O, 3 : 1). Fraction 3.2.3.8 (53 mg)
was purified by HPLC (ODS, MeOH–H2O, 3 : 1) to give compound 2
(24 mg). Another compounds were obtained following yield 4 (28 mg), 5
(100 mg), 6 (40 mg), 7 (31 mg), 8 (10 mg), 9 (19 mg), 10 (126 mg), 11
(278 mg), 12 (183 mg), 13 (8 mg), 14 (24 mg), 15 (5 mg), 16 (28 mg), 17
(5.5 g), 18 (16 mg), 19 (2 mg), 20 (39 mg), 21 (15 mg), 22 (16 mg), 23
(80 mg), 24 (7 mg), 25 (325 mg), 26 (4 mg), 27 (21 mg), 28 (20 mg), 29
(2 mg), 30 (32 mg), 31 (15 mg), 32 (57 mg) and 33 (14 mg).
Tschimganic Ester A (1): [a]D25 25.0° (c50.2, MeOH); IR nmaxKBr cm21:
3422, 3109, 2975, 1730, 1700, 1625, 1573, 1451, 1249, 1100; UV lmaxMeOH
nm (log e): 321 (3.89), 264 (4.02), 250 (4.10); HR-FAB-MS m/z 475.1594
[M1Na]1, (Calcd for C22H28O10Na, 475.1580); 
1H-NMR (CD3OD) dH: 7.78
(H-4, d, J59.5 Hz), 7.47 (H-5, d, J58.7 Hz), 7.01 (H-6, d, J58.7 Hz), 6.23
(H-3, d, J59.5 Hz), 5.23 (H-29, dd, J51.9, 9.3 Hz), 3.99 (3H, s, OCH3), 3.90
(H-30, br s), 3.86 (H-50, ddd, J53.4, 9.3, 12.9 Hz), 3.45 (H-19, t, J512.5 Hz),
3.26 (H-40, dd, J52.9, 9.3 Hz), 3.08 (H-19, dd, J51.9, 12.5 Hz), 1.89 (H-60,
dd, J53.4, 12.9 Hz), 1.71 (H-20, dd, J52.6, 14.5 Hz), 1.63 (H-60, t, J5
12.9 Hz), 1.41 (H-20, dd, J52.9, 14.5 Hz), 1.31 (H-49, 3H, s), 1.29 (H-59,
3H, s); 13C-NMR data see Table 1.
Tschimganic Ester B (2): [a]D25 28.0° (c50.2, MeOH); IR nmaxKBr cm21:
3400, 3071, 1727, 1707, 1630, 1597, 1458, 1402, 1331, 1216, 883; UV
lmaxMeOH nm (log e): 309 (4.02), 267 (4.21), 249 (4.30), 221 (4.42); HR-FAB-
MS m/z 501.1386 [M1Na]1, (Calcd for C23H26O11Na, 501.1373); 
1H-NMR
(CD3OD) dH: 8.12 (H-4, d, J59.8 Hz), 7.78 (H-9, d, J52.0 Hz), 7.19 (H-10,
d, J52.0 Hz), 7.12 (H-8, s), 6.23 (H-3, d, J59.8 Hz), 5.34 (H-29, d,
J59.8 Hz), 4.89 (H-19, d, J59.8 Hz), 4.67 (H-19, t, J59.8 Hz), 4.09 (H-30,
m), 4.02 (H-50, ddd, J53.2, 9.2, 12.5 Hz), 3.40 (H-40, m), 2.18 (H-60, m),
2.12 (H-20, 2H, m), 1.89 (H-60, t, J512.5 Hz), 1.32 (H-59, 3H, s), 1.30 (H-
49, 3H, s); 13C-NMR data see Table 1.
Tschimganic Ester C (3): [a]D25 28.4° (c50.2, MeOH); IR nmaxKBr cm21:
3420, 3075, 1729, 1707, 1623, 1610, 1589, 1460, 1334, 1212, 1101, 874;
UV lmaxMeOH nm (log e): 309 (3.97), 267 (4.15), 248 (4.25), 218 (4.29); HR-
FAB-MS m/z 501.1342 [M1Na]1, (Calcd for C23H26O11Na, 501.1373); 
1H-
NMR (CD3OD) dH: 7.98 (H-4, d, J59.8 Hz), 7.87 (H-9, d, J52.0 Hz), 7.51
(H-5, s), 6.87 (H-10, d, J52.0 Hz), 6.31 (H-3, d, J59.8 Hz), 5.28 (H-29, d,
J59.8 Hz), 4.92 (H-19, d, J59.8 Hz), 4.62 (H-19, t, J59.8 Hz), 4.09 (H-30,
m), 3.99 (H-50, ddd, J53.2, 9.5, 12.5 Hz), 3.40 (H-40, m), 2.20 (H-60, m),
2.12 (H-20, 2H, m), 1.92 (H-60, t, J512.5 Hz), 1.28 (H-59, 3H, s), 1.26 (H-
49, 3H, s); 13C-NMR data see Table 1.
Meranzin Hydrate: 13C-NMR (CD3OD) dC: 163.8 (C-1), 162.5 (C-7),
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154.6 (C-8a), 146.4 (C-4), 128.4 (C-5), 117.2 (C-4a), 114.3 (C-8), 113.0 (C-
3), 109.1 (C-6), 78.8 (C-29), 74.1 (C-39), 26.3 (C-19), 25.6 (C-49, 59), 56.8
(OCH3).
Peracetylation of (2)-Quinic Acid (2)-Quinic acid (400 mg) was
acetylated with acetic anhydride (10 ml) and pyridine (10 ml) at room tem-
perature overnight. The products were purified by using GPC eluted with
CHCl3, obtained the pure peracetate of quinic acid (2a).
2a: 1H-NMR (CDCl3) dH: 5.55 (1H, d, J51.5 Hz), 5.42 (1H, m), 4.95
(1H, dd, J52.6, 9.1 Hz), 2.70 (1H, br d, J512.1 Hz), 2.61 (1H, br d,
J512.6 Hz), 2.36 (1H, dd, J51.5, 12.1 Hz), 2.15 (3H, s), 2.10 (3H, s), 2.06
(3H, s), 2.04 (3H, s), 1.98 (1H, t, J512.6 Hz). EI-MS: m/z 360 [M]1.
Esterification of Oxypeucedanin Hydrate (12) A solution of
oxypeucedanin hydrate (12) (100 mg), quinic acid peracetate (2a) (100 mg),
DCC (60 mg) and 4-pyrrolidinopyridine (40 mg) in CH2Cl2 (20 ml) was al-
lowed to stand at room temperature overnight. The N,N-dicyclohexyl urea
was filtered and the filtrate washed with water, 5% acetic acid solution and
again with water, dried over MgSO4 and the solvent evaporated in vacuo to
give the ester. The residue was purified by GPC, quinic ester of oxy-
peucedanin hydrate (2b; 45 mg) was obtained.
2b: 1H-NMR (CDCl3) dH: 8.08, 8.06 (H-4), 7.62 (2H, H-9), 7.15 (2H, H-
8), 6.97, 6.95 (H-10), 6.29, 6.27 (H-3), 2.14 (3H, OAc), 2.10 (3H, OAc),
2.08 (3H, OAc), 2.07 (3H, OAc), 2.01 (9H, OAc33), 2.00 (3H, OAc), 1.38
(3H, CH3), 1.36 (3H, CH3), 1.31 (3H, CH3), 1.29 (3H, CH3). FAB-MS: m/z
647 [M1H]1.
Acethylation of 2b The compound 2b (40 mg) was acetylated by using
the same method with acetic anhydride as that of esterification of oxy-
peucedanin hydrate, to give the compound 2c (2 mg).
2c: 1H-NMR (CDCl3) dH: 8.08 (2H, H-4), 7.64 (2H, H-9), 7.18 (2H, H-8),
6.97, 6.95 (H-10), 6.31, 6.27 (2H, H-3), 2.14 (3H, OAc), 2.13 (3H, OAc),
2.09 (3H, OAc), 2.08 (3H, OAc), 2.07 (3H, OAc), 2.03 (6H, OAc32), 2.02
(3H, OAc), 2.00 (3H, OAc), 1.98 (6H, OAc32), 1.59 (6H, CH332), 1.57
(6H, CH332). FAB-MS: m/z 711 [M1Na]
1, 689 [M1H]1.
Acetylation of Tschimganic Ester B Tschimganic ester B (10 mg) was
acetylated by using the same method as that of esterification of oxy-
peucedanin hydrate, obtained the tetraacetate of tschimganic ester B (2c9;
1 mg). This was identified by 1H, TLC and FAB-MS comparison to the com-
pound 2c.
Esterification with Chiral Anisotropic Reagents [(R,S)-MTPA] Three
equivalent of 2,4,6-trinitrochlorobenzene, MTPA and an alcohol [8 (8 mg), 9
(17 mg), 11 (10 mg), 12 (16 mg), 14 (3 mg), 20 (5 mg), 27 (3 mg), 28 (3 mg),
31 (5 mg)] were dissolved in pyridine dehydrated (5 ml). After the mixture
was stirred for 8 h, CHCl3 was added, and the organic layer was washed with
8% aqueous sodium hydrogen carbonate and brine, dried over Na2SO4 and
concentrated to yield a crude ester. A crude ester was purified by GPC using
CHCl3.
(29R)-20 [(R)-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.53 (0.25H, H-4),
7.32 (0.25H, H-5), 6.77 (0.25H, H-6), 6.15 (0.25H, H-3), 5.81 (0.25H, H-
29), 5.05 (0.25H, H-49), 4.95 (0.25H, H-49), 3.08 (0.25H, H-19), 1.90
(0.75H, H-59).
(29S )-20 [(R)-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.60 (0.75H, H-4),
7.40 (0.75H, H-5), 6.84 (0.75H, H-6), 6.22 (0.75H, H-3), 5.72 (0.75H, H-
29), 4.96 (0.75H, H-49), 4.90 (0.75H, H-49), 3.15 (0.75H, H-19), 1.80
(2.25H, H-59).
(29R)-20 [(S )-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.61 (0.25H, H-4),
7.34 (0.25H, H-5), 6.84 (0.25H, H-6), 6.23 (0.25H, H-3), 5.73 (0.25H, H-
29), 4.96 (0.25H, H-49), 4.90 (0.25H, H-49), 3.16 (0.25H, H-19), 1.81
(0.75H, H-59).
(29S )-20 [(S )-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.53 (0.75H, H-4),
7.32 (0.75H, H-5), 6.78 (0.75H, H-6), 6.16 (0.75H, H-3), 5.82 (0.75H, H-
29), 5.05 (0.75H, H-49), 4.96 (0.75H, H-49), 3.10 (0.75H, H-19), 1.91
(2.25H, H-59).
27 [(S )-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.48 (H-4), 6.81 (H-5), 6.24
(H-3), 5.47 (H-29), 3.93 (OCH3), 3.24 (H-19), 2.82 (H-19), 1.33, 1.31
(CH332).
31 [MTPA] Ester: 1H-NMR (CDCl3) dH: 6.38 (H-3), 5.34 (H-29), 2.92 (H-
19), 2.79 (H-19), 1.11, 1.09 (CH332).
8 [(R)-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.75, 7.73 (each 0.5H, H-4),
6.81, 6.79 (each 0.5H, H-10), 6.34, 6.33 (each 0.5H, H-3), 5.59 (1H, H-29),
4.92, 4.83 (each 0.5H, H-19), 4.69 (1H, H-19), 1.40, 1.39, 1.28, 1.24 (each
1.5H, CH334).
9 [(S )-MTPA] Ester: 1H-NMR (CDCl3) dH: 8.01 (0.6H, H-4), 7.92 (0.4H,
H-4), 6.89 (0.6H, H-10), 6.83 (0.4H, H-10), 6.23 (0.6H, H-3), 6.20 (0.4H,
H-3), 5.90 (1H, H-29), 5.26, 5.19 (each 0.6H, H-49), 5.14, 5.12 (each 0.4H,
H-49), 1.89 (1.2H, CH3), 1.81 (1.8H, CH3).
11 [(R)-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.94, 7.91 (each 0.5H, H-4),
7.62, 7.60 (each 0.5H, H-9), 6.92, 6.87 (each 0.5H, H-3), 5.59 (1H, H-29),
4.92, 4.83 (each 0.5H, H-19), 4.69 (1H, H-19), 1.40, 1.39, 1.28, 1.24 (each
1.5H, CH334).
12 [(R)-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.97, 7.95 (each 0.5H, H-4),
6.96, 6.89 (each 0.5H, H-10), 6.21, 6.18 (each 0.5H, H-3), 5.57, 5.51 (each
0.5H, H-29), 1.36, 1.35, 1.33, 1.28 (each 1.5H, CH334).
14 [(S )-MTPA] Ester: 1H-NMR (CDCl3) dH: 7.76 (0.5H, H-4), 7.75 (1H,
H-4), 6.84 (0.5H, H-10), 6.81 (1H, H-10), 6.38 (0.5H, H-3), 6.36 (1H, H-3),
5.78 (0.5H, H-29), 5.77 (1H, H-29), 5.04 (0.5H, H-19), 4.91 (1H, H-19), 4.77
(0.5H, H-19), 4.72 (1H, H-19), 1.79, 1.76 (each 1.5H, CH3), 1.64, 1.57 (each
3H, CH3).
28 [MTPA] Ester: 1H-NMR (CDCl3) dH: 7.95, 7.93 (each 0.5H, H-4),
6.96, 6.89 (each 0.5H, H-10), 6.21, 6.15 (each 0.5H, H-3), 5.65 (1H, H-29),
4.84 (each 0.5H, H-19), 4.67 (1H, H-19), 4.56 (each 0.5H, H-19), 1.28, 1.27,
1.23, 1.21 (each 1.5H, CH334).
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